SCHEMBL5075702

SCHEMBL5075702

Nc1nc(=O)n([C@H]2C=C[C@@H](CO)O2)cc1NC=O

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 6/20 0.43
ALB P02768 4/20 0.43
ALDH1A1 P00352 3/20 0.43
POLB P06746 2/20 0.43
BLM P54132 2/20 0.43
ADRA1A P35348 1/20 0.43
DNMT1 P26358 4/20 0.32
PDE3A Q14432 3/20 0.32
PDE4D Q08499 1/20 0.32
SLC29A1 Q99808 1/20 0.32
MTOR P42345 2/20 0.32
SMN1; SMN2 Q16637 2/20 0.32
THRB P10828 1/20 0.32
MDM2 Q00987 1/20 0.32
NCOA1 Q15788 1/20 0.32
NCOA3 Q9Y6Q9 1/20 0.32
GMNN O75496 1/20 0.32
TP53 P04637 1/20 0.32
NFKB1 P19838 1/20 0.32
THPO P40225 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30667453 0.80 LMNA (0.46) LMNAALBALDH1A1POLBBLM
Dexelvucitabine SCHEMBL599014 0.80 ALB (0.55) LMNAALBALDH1A1POLBBLM
SCHEMBL4749034 0.80 LMNA (0.59) LMNAALBALDH1A1POLBBLM
Elvucitabine SCHEMBL3298257 0.80 ALB (0.55) LMNAALBALDH1A1POLBBLM
SCHEMBL5952944 0.80 LMNA (0.59) LMNAALBALDH1A1POLBBLM
Elvucitabine SCHEMBL1649928 0.80 ALB (0.55) LMNAALBALDH1A1POLBBLM
SCHEMBL5074429 0.79 ALB (0.39) LMNAALBALDH1A1POLBBLM
SCHEMBL5074416 0.78 ALB (0.39) LMNAALBALDH1A1POLBBLM
SCHEMBL7124525 0.78 BLM (0.63) LMNAALBALDH1A1POLBBLM
SCHEMBL5076232 0.75 ABL1 (0.45) LMNAALBALDH1A1POLBDNMT1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080293668-A1 [5-carboxamido or 5-fluoro]-[2',3'-unsaturated or 3'-modified]-pyrimidine nucleosides SCHINAZI RAYMOND F 2008-11-27 US claimed
US-20040167140-A1 [5-carboxamido or 5-fluoro]-[2',3'-unsaturated or 3'-modified]-pyrimidine nucleosides EMORY UNIVERSITY 2004-08-26 US claimed
EP-1361227-A2 [5-carboxamide or 5-fluoro]-[2', 3'-unsaturated or 3'-modifield]-pyrimidine nucleosides Emory University (US) 2003-11-12 EP claimed
US-20020198173-A1 [5-carboxamido or 5-fluoro] - [2' ,3' -unsaturated or 3' -modified] - pyrimidine nucleosides EMORY UNIVERSITY 2002-12-26 US claimed
US-20080293668-A1 [5-carboxamido or 5-fluoro]-[2',3'-unsaturated or 3'-modified]-pyrimidine nucleosides SCHINAZI RAYMOND F 2008-11-27 US disclosed
US-7419966-B2 [5-carboxamido or 5-fluoro]-[2′,3′-unsaturated or 3′-modified]-pyrimidine nucleosides EMORY UNIVERSITY (US) 2008-09-02 US disclosed
US-20040167140-A1 [5-carboxamido or 5-fluoro]-[2',3'-unsaturated or 3'-modified]-pyrimidine nucleosides EMORY UNIVERSITY 2004-08-26 US disclosed
US-6680303-B2 VIRICIDES FOR TREATING HIV AND HEPATITIS VIRUS EMORY UNIVERSITY 2004-01-20 US disclosed
EP-1361227-A2 [5-carboxamide or 5-fluoro]-[2', 3'-unsaturated or 3'-modifield]-pyrimidine nucleosides Emory University (US) 2003-11-12 EP disclosed
US-20020198173-A1 [5-carboxamido or 5-fluoro] - [2' ,3' -unsaturated or 3' -modified] - pyrimidine nucleosides EMORY UNIVERSITY 2002-12-26 US disclosed
US-6391859-B1 HUMAN IMMUNODEFICIENCY VIRUS; VIRICIDES EMORY UNIVERSITY 2002-05-21 US disclosed
US-6232300-B1 ADMINISTERING AS HEPATITIS B VIRICIDE EMORY UNIVERSITY 2001-05-15 US disclosed
US-5905070-A HUMAN T-CELL LEUKEMIA/LYMPHOMA AND HEPATITIS B VIRICIDES; AIDS EMORY UNIVERSITY (US) 1999-05-18 US disclosed
US-5703058-A TREATMENT OF HIV AND HEPATITIS B EMORY UNIVERSITY (US) 1997-12-30 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080293668-A1 [5-carboxamido or 5-fluoro]-[2',3'-unsaturated or 3'-modified]-pyrimidine nucleosides DUT, NUDT1, PNP LMNA 1598/4885ALB 1099/4885ALDH1A1 1880/4885
US-20020198173-A1 [5-carboxamido or 5-fluoro] - [2' ,3' -unsaturated or 3' -modified] - pyrimidine nucleosides DUT, NUDT1, PNP LMNA 1735/4885ALB 1169/4885ALDH1A1 1716/4885
US-20040167140-A1 [5-carboxamido or 5-fluoro]-[2',3'-unsaturated or 3'-modified]-pyrimidine nucleosides DUT, NUDT1, PNP LMNA 1735/4885ALB 1169/4885ALDH1A1 1716/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.